EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update

Bernhard Hellmich, Beatriz Sanchez-Alamo, Jan H. Schirmer, Alvise Berti, Daniel Blockmans, Maria C. Cid, Julia U. Holle, Nicole Hollinger, Omer Karadag, Andreas Kronbichler, Mark A. Little, Raashid A. Luqmani, Alfred Mahr, Peter A. Merkel, Aladdin J. Mohammad, Sara Monti, Chetan B. Mukhtyar, Jacek Musial, Fiona Price-Kuehne, Mårten SegelmarkY. K. Onno Teng, Benjamin Terrier, Gunnar Tomasson, Augusto Vaglio, Dimitrios Vassilopoulos, Peter Verhoeven, David Jayne

Research output: Contribution to journalArticlepeer-review

106 Citations (Scopus)
3 Downloads (Pure)


Background: Since the publication of the EULAR recommendations for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) in 2016, several randomised clinical trials have been published that have the potential to change clinical care and support the need for an update. Methods: Using EULAR standardised operating procedures, the EULAR task force undertook a systematic literature review and sought opinion from 20 experts from 16 countries. We modified existing recommendations and created new recommendations. Results: Four overarching principles and 17 recommendations were formulated. We recommend biopsies and ANCA testing to assist in establishing a diagnosis of AAV. For remission induction in life-threatening or organ-threatening AAV, we recommend a combination of high-dose glucocorticoids (GCs) in combination with either rituximab or cyclophosphamide. We recommend tapering of the GC dose to a target of 5 mg prednisolone equivalent/day within 4-5 months. Avacopan may be considered as part of a strategy to reduce exposure to GC in granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA). Plasma exchange may be considered in patients with rapidly progressive glomerulonephritis. For remission maintenance of GPA/MPA, we recommend rituximab. In patients with relapsing or refractory eosinophilic GPA, we recommend the use of mepolizumab. Azathioprine and methotrexate are alternatives to biologics for remission maintenance in AAV. Conclusions: In the light of recent advancements, these recommendations provide updated guidance on AAV management. As substantial data gaps still exist, informed decision-making between physicians and patients remains of key relevance.

Original languageEnglish
Pages (from-to)30-47
Number of pages18
JournalAnnals of the Rheumatic Diseases
Issue number1
Early online date16 Mar 2023
Publication statusPublished - Jan 2024


  • cyclophosphamide
  • granulomatosis with polyangiitis
  • rituximab
  • systemic vasculitis

Cite this